CareDx, Inc. (CDNA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CDNA SEC filings page.
CareDx, Inc. (CDNA) reported $458.1M in revenue over the twelve months to Jun 30, 2026, up 34.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue recovered, but profitability proved uneven: positive earnings in FY2024 gave way to a loss despite further growth.
In FY2025, revenue rose while net income swung to a loss of$21.4M , even as operating cash flow stayed positive. Accounts receivable fell from$64.6M to$42.6M , making working-capital release a plausible contributor to cash generation rather than evidence that earnings and cash fully agreed.
The business did not show a simple scale-driven profit pattern: revenue increased from
Liabilities stayed near
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of CareDx, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
CareDx, Inc. has an operating margin of -8.1%, meaning the company loses $8 on every $100 of revenue. This results in a profitability score of 18/100. This is down from 12.2% the prior year.
CareDx, Inc.'s revenue grew 13.8% year-over-year to $379.8M, a solid pace of expansion. This earns a growth score of 78/100.
CareDx, Inc. carries a low D/E ratio of 0.36, meaning only $0.36 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 66/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.86, CareDx, Inc. holds $2.86 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 77/100.
Not available for CareDx, Inc., and counted as zero in the overall score.
CareDx, Inc. posts a -7.0% return on equity (ROE), meaning it loses $7 for every $100 of shareholders' equity. This results in a returns score of 18/100. This is down from 13.9% the prior year.
CareDx, Inc. scores 17.99, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.5B) relative to total liabilities ($110.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
CareDx, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
CareDx, Inc. reported a net loss of $21.4M while generating $42.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
CareDx, Inc. generated $131.9M in revenue in Q2 2026. This represents an increase of 52.2% from the same quarter a year earlier. Against the prior quarter it is up 12.1%.
CareDx, Inc.'s EBITDA was $116.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 1668.2% from the same quarter a year earlier. Against the prior quarter it is up 2176.5%.
CareDx, Inc. reported $110.6M in net income in Q2 2026. This represents an increase of 1391.3% from the same quarter a year earlier. Against the prior quarter it is up 3838.6%.
CareDx, Inc. earned $2.07 per diluted share (EPS) in Q2 2026. This represents an increase of 1393.8% from the same quarter a year earlier. Against the prior quarter it is up 4040.0%.
Cash & Balance Sheet
CareDx, Inc. generated $28.7M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 223.4% from the same quarter a year earlier. Against the prior quarter it is up 5492.6%.
CareDx, Inc. held $373.6M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
CareDx, Inc.'s operating margin was 85.8% in Q2 2026, reflecting core business profitability. This is up 98.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 84.8 percentage points.
CareDx, Inc.'s net profit margin was 83.9% in Q2 2026, showing the share of revenue converted to profit. This is up 93.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 81.5 percentage points.
CareDx, Inc.'s ROE was 26.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 28.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 25.1 percentage points.
Not reported for Q2 2026.
Capital Allocation
CareDx, Inc. invested $22.4M in research and development in Q2 2026. This represents an increase of 33.0% from the same quarter a year earlier. Against the prior quarter it is up 4.5%.
CareDx, Inc. invested $1.9M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 84.5% from the same quarter a year earlier. Against the prior quarter it is down 51.3%.
Not reported for Q2 2026.
CDNA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $131.9M+52.2% | $117.7M+39.0% | $108.4M+25.2% | $100.1M+20.7% | $86.7M-6.1% | $84.7M+17.5% | $86.6M+32.0% | $82.9M+23.4% |
| R&D Expenses | $22.4M+33.0% | $21.4M+15.6% | $19.3M+16.2% | $16.8M-4.1% | $16.8M-14.5% | $18.5M-1.0% | $16.6M-11.7% | $17.5M-8.0% |
| SG&A Expenses | $40.9M+47.8% | $30.5M+33.9% | $28.7M-11.3% | $28.4M-10.4% | $27.7M-10.4% | $22.8M-24.5% | $32.3M+17.6% | $31.7M-6.5% |
| Operating Income | $113.2M+1118.1% | $1.2M+109.0% | -$6.0M-107.2% | -$246K+98.2% | -$11.1M-51.8% | -$13.4M+40.7% | $84.4M+168.8% | -$13.7M+52.3% |
| EBITDA | $116.0M+1668.2% | $5.1M+152.1% | -$2.2M-102.5% | $3.6M+134.8% | -$7.4M-95.5% | -$9.8M+47.9% | $87.7M+173.7% | -$10.3M+59.2% |
| Income Tax | $3.9M+3417.9% | -$32K-155.2% | $345K+101.8% | -$15K-107.5% | -$117K-631.8% | $58K+169.9% | $171K+3.6% | $200K+350.0% |
| Net Income | $110.6M+1391.3% | $2.8M+127.1% | -$4.1M-104.7% | $1.7M+115.7% | -$8.6M-85.3% | -$10.4M+47.9% | $87.7M+174.3% | -$10.6M+54.7% |
| EPS (Basic) | $2.15+1443.8% | $0.05+126.3% | -$0.08-104.8% | $0.03+115.0% | -$0.16-77.8% | -$0.19+50.0% | $1.67+175.9% | -$0.20+53.5% |
| EPS (Diluted) | $2.07+1393.8% | $0.05+126.3% | -$0.08-105.0% | $0.03+115.0% | -$0.16-77.8% | -$0.19+50.0% | $1.60+172.7% | -$0.20+53.5% |
| Diluted Shares (Avg) | 53M-1.6% | 53M-3.9% | N/A | 54M+1.6% | 54M+4.0% | 55M+6.9% | N/A | 53M-2.4% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
CDNA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $533.0M+20.0% | $411.1M-16.0% | $413.2M-15.8% | $432.3M-9.4% | $444.3M-4.8% | $489.6M+8.2% | $491.1M+5.2% | $477.0M-4.8% |
| Current Assets | $429.2M+39.7% | $269.4M-23.1% | $257.1M-26.9% | $300.3M-10.1% | $307.3M-4.2% | $350.2M+15.6% | $351.8M+12.2% | $334.1M-3.2% |
| Cash & Equivalents | $373.6M+447.8% | $77.9M-12.2% | $65.4M-43.0% | $91.4M-4.2% | $68.2M-28.8% | $88.7M-4.9% | $114.7M+39.5% | $95.4M+25.6% |
| Short-Term Investments | $0-100.0% | $109.3M-23.2% | $111.8M-23.4% | $102.8M-29.3% | $118.0M-11.3% | $142.2M+15.9% | $146.0M-4.7% | $145.5M-24.3% |
| Inventory | $7.0M-75.0% | $26.4M+15.2% | $26.7M+36.9% | $28.3M+47.1% | $27.9M+45.1% | $22.9M+13.9% | $19.5M+0.2% | $19.3M+7.1% |
| Accounts Receivable | $34.4M-49.0% | $44.6M-37.6% | $42.6M-34.0% | $47.8M-28.2% | $67.4M+1.8% | $71.5M+18.8% | $64.6M+26.5% | $66.6M+28.9% |
| Long-Term Investments | $0 | $10.9M | $24.2M | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $36.0M-10.8% | $40.3M0.0% | $40.3M0.0% | $40.3M0.0% | $40.3M0.0% | $40.3M0.0% | $40.3M0.0% | $40.3M+0.3% |
| Total Liabilities | $107.4M-8.1% | $97.5M-11.6% | $110.1M-2.2% | $121.2M-40.5% | $116.9M-42.2% | $110.3M-43.8% | $112.6M-45.2% | $203.7M+90.3% |
| Current Liabilities | $93.7M+0.6% | $79.2M-7.2% | $89.8M+0.5% | $99.0M+21.6% | $93.2M+19.0% | $85.3M+21.5% | $89.4M+14.5% | $81.4M+12.1% |
| Non-Current Liabilities | $13.7M-42.2% | $18.4M-26.5% | $20.3M-12.8% | $22.1M-81.9% | $23.7M-80.8% | $25.0M-80.2% | $23.2M-81.8% | $122.3M+255.8% |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Total Equity | $425.6M+30.0% | $313.5M-17.3% | $303.1M-19.9% | $311.1M+13.9% | $327.4M+23.7% | $379.3M+48.1% | $378.4M+44.8% | $273.2M-30.7% |
| Retained Earnings | -$505.4M+27.3% | -$732.5M-15.1% | -$618.9M+1.2% | -$719.0M-2.1% | -$695.2M+0.2% | -$636.6M+8.5% | -$626.2M+7.7% | -$704.3M-31.8% |
CDNA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $30.6M+209.3% | $4.3M+116.3% | $21.4M-2.4% | $37.4M+198.3% | $9.9M-47.8% | -$26.6M-73.6% | $21.9M+361.2% | $12.5M+223.0% |
| Depreciation & Amortization | $2.8M-24.5% | $3.9M+8.3% | $3.9M+15.5% | $3.8M+9.9% | $3.7M+5.1% | $3.6M-5.8% | $3.4M-7.4% | $3.5M-5.3% |
| Stock-Based Compensation | $10.7M+13.1% | $9.8M+9.8% | N/A | $8.4M-50.3% | $9.4M-42.5% | $8.9M-46.1% | N/A | $16.9M+33.6% |
| Capital Expenditures | $1.9M+84.5% | $3.8M+134.3% | N/A | N/A | $1.0M | $1.6M | N/A | N/A |
| Free Cash Flow | $28.7M+223.4% | $514K+101.8% | N/A | N/A | $8.9M | -$28.2M | N/A | N/A |
| Investing Cash Flow | $280.6M+1099.2% | $11.1M+734.6% | -$34.9M-1553.9% | $12.3M+185.7% | $23.4M+301.2% | $1.3M-95.2% | -$2.1M-105.1% | -$14.4M-861.7% |
| Financing Cash Flow | -$15.5M+71.2% | -$2.9M-352.7% | -$12.5M-1280.1% | -$26.5M-1962.0% | -$53.8M-1009.5% | -$643K+49.6% | -$903K+96.6% | $1.4M+5788.0% |
| Share Buybacks | N/A | N/A | $12.2M | $25.6M | $50.0M | $0-100.0% | $0-100.0% | $0-100.0% |
Not reported in any period shown, so not listed: Dividends Paid.
CDNA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 85.8%+98.6pp | 1.0%+16.8pp | -5.6%-103.0pp | -0.3%+16.3pp | -12.8%-4.9pp | -15.8%+15.5pp | 97.5% | -16.6%+26.3pp |
| Net Margin | 83.9%+93.7pp | 2.4%+14.6pp | -3.8% | 1.7%+14.5pp | -9.9%-4.9pp | -12.2%+15.4pp | 101.3% | -12.8%+22.1pp |
| Return on Equity | 26.0%+28.6pp | 0.9%+3.6pp | -1.4%-24.5pp | 0.5%+4.4pp | -2.6%-0.9pp | -2.7%+5.0pp | 23.2%+68.4pp | -3.9%+2.1pp |
| Return on Assets | 20.8%+22.7pp | 0.7%+2.8pp | -1.0%-18.9pp | 0.4%+2.6pp | -1.9%-0.9pp | -2.1%+2.3pp | 17.9%+43.2pp | -2.2%+2.5pp |
| Current Ratio | 4.58+1.3x | 3.40-0.7x | 2.86-1.1x | 3.03-1.1x | 3.30-0.8x | 4.11-0.2x | 3.94-0.1x | 4.10-0.6x |
| Debt-to-Equity | 0.25-0.1x | 0.310.0x | 0.36+0.1x | 0.39+0.4x | 0.36+0.4x | 0.29-0.5x | 0.30-0.5x | 0.00-0.3x |
| Asset Turnover | 0.25+0.1x | 0.29+0.1x | 0.26+0.1x | 0.23+0.1x | 0.200.0x | 0.170.0x | 0.180.0x | 0.170.0x |
| FCF Margin | 21.8%+11.5pp | 0.4%+33.8pp | N/A | N/A | 10.3% | -33.3% | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CareDx, Inc. CDNA | FY2025 | $379.8M | -$21.4M | -5.6% | $3.5B | 43/100 |
| Myriad Genetics Inc MYGN | FY2025 | $824.5M | -$366.0M | -44.4% | $434.2M | 38/100 |
| Fulgent Genetics, Inc. FLGT | FY2025 | $322.7M | -$60.5M | -18.8% | $591.0M | 44/100 |
| Castle Biosciences, Inc. CSTL | FY2025 | $344.2M | -$24.2M | -7.0% | $1.1B | 61/100 |
| Personalis, Inc. PSNL | FY2025 | $69.6M | -$81.3M | N/A | $1.7B | 51/100 |
| Opko Health Inc. OPK | FY2025 | $606.9M | N/A | N/A | $1.2B | 40/100 |
Where CareDx, Inc. Ranks
Frequently Asked Questions
What is CareDx, Inc.'s annual revenue?
CareDx, Inc. (CDNA) reported $379.8M in total revenue for fiscal year 2025. This represents a 13.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is CareDx, Inc.'s revenue growing?
CareDx, Inc. (CDNA) revenue grew by 13.8% year-over-year, from $333.8M to $379.8M in fiscal year 2025.
Is CareDx, Inc. profitable?
No, CareDx, Inc. (CDNA) reported a net income of -$21.4M in fiscal year 2025, with a net profit margin of -5.6%.
What is CareDx, Inc.'s EBITDA?
CareDx, Inc. (CDNA) had EBITDA of -$15.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is CareDx, Inc.'s operating margin?
CareDx, Inc. (CDNA) had an operating margin of -8.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is CareDx, Inc.'s net profit margin?
CareDx, Inc. (CDNA) had a net profit margin of -5.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is CareDx, Inc.'s return on equity (ROE)?
CareDx, Inc. (CDNA) has a return on equity of -7.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is CareDx, Inc.'s operating cash flow?
CareDx, Inc. (CDNA) generated $42.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are CareDx, Inc.'s total assets?
CareDx, Inc. (CDNA) had $413.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does CareDx, Inc. spend on research and development?
CareDx, Inc. (CDNA) invested $71.4M in research and development during fiscal year 2025.
What is CareDx, Inc.'s current ratio?
CareDx, Inc. (CDNA) had a current ratio of 2.86 as of fiscal year 2025, which is generally considered healthy.
What is CareDx, Inc.'s debt-to-equity ratio?
CareDx, Inc. (CDNA) had a debt-to-equity ratio of 0.36 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is CareDx, Inc.'s return on assets (ROA)?
CareDx, Inc. (CDNA) had a return on assets of -5.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is CareDx, Inc.'s P/E ratio?
CareDx, Inc. (CDNA) trades at 31.3x earnings, its market capitalization divided by net income of $111.0M net income, trailing 12 months to June 30, 2026. The market capitalization is $3.5B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CareDx, Inc.'s price-to-sales ratio?
CareDx, Inc. (CDNA) trades at 7.6x sales, its market capitalization divided by revenue of $458.1M revenue, trailing 12 months to June 30, 2026. The market capitalization is $3.5B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CareDx, Inc.'s Altman Z-Score?
CareDx, Inc. (CDNA) has an Altman Z-Score of 17.99, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is CareDx, Inc.'s Piotroski F-Score?
CareDx, Inc. (CDNA) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CareDx, Inc.'s earnings high quality?
CareDx, Inc. (CDNA) reported a net loss of $21.4M while generating $42.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is CareDx, Inc.?
CareDx, Inc. (CDNA) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.